<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1435">
  <stage>Registered</stage>
  <submitdate>6/07/2006</submitdate>
  <approvaldate>7/07/2006</approvaldate>
  <actrnumber>ACTRN12606000289516</actrnumber>
  <trial_identification>
    <studytitle>Pulmonary Artery Remodelling With Bosentan</studytitle>
    <scientifictitle>Open Label, Non Comparative Study to Investigate the Effect of Bosentan on Pulmonary Artery Remodelling in Pulmonary Arterial Hypertension (PAH)</scientifictitle>
    <utrn />
    <trialacronym>PARBO</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension, Pulmonary</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bosentan be orally administered at 62.5mg bid for 4 weeks, followed by a target dose of 125mg bid for 6 months</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline (BL) to 6 mths in the intravascular ultrasound (IVUS)-derived measurement of pulmonary artery wall thickness.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from BL to 6 mths in pulmonary microvascular circulation (PMVC) dilator responses to actylcholine (Ach).</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from BL to 6 mths in each of the IVUS derived pulmonary artery parameters.; Change from BL to 6 mths in PMVC (dilator responses to sodium nitroprusside.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between the change from BL to 6 mths of each of the IVUS-derived parameters and the PMVC dilator responses versus changes in pulmonary vascular resistance (PVR).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between the change from BL to 6 mths of each of the IVUS-derived parameters and the PMVC dilator responses versus changes in six minute walk distance (6MWD).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Symptomatic (modified New York Heart Associate (NYHA) class III) iPAH or PAH-SScPAH confirmed by right heart catheterisation performed within 3 months before enrolment, mean pulmonary artery pressure (mPAP) &gt; 25mmHg, pulmonary capillary wedge pressure (PCWP) &lt; 15 mmHg and PVR &gt; 3 mmHg/l/minWomen of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception during study treatment and for 3 months after study treatment termination.Bosentan naïve patientsSigned written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>PAH other than iPAH or PAH-SScSignificant vasoreactivity during right heart catheterization defined as a fall in mPAP to &lt; 40 mmHg with a decrease = 10 mmHg and with a normal cardiac index (= 2.5 l/min.m2)Severe obstructive lung disease: Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Vapacity (FVC) &lt; 0.5Severe restrictive lung disease: Total Lung Capacity (TLC) &lt; 0.7 of normal predicted valueHemoglobin &lt;75% of the lower limit of the normal rangeSystolic blood pressure &lt; 85 mmHgBody weight &lt; 40 kgPregnancy or breast-feedingModerate to severe hepatic impairment, i.e., Child-Pugh Class B or C.Baseline aminotransferases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT) &gt; 3 times the upper limit of the normal (ULN) range.Treatment for iPAH or PAH-SSc within 1 month before start of study treatment, excluding warfarin and acute administration of vasodilators for vascular reactivity testing during heart catheterization.Treatment with epoprostenol or other prostacyclin analogs for iPAH or PAH-SSc within 1 month before start of study treatmentTreatment with glibenclamide (glyburide), fluconazole ketoconazole or ritonavir within 1 week before start of study treatment.Current treatment with cyclosporine A or tacrolimusHypersensitivity to bosentan or any of the excipients of its formulation.Patient who received an investigational drug (such as sildenafil) within 3 months before start of study treatmentConditions that prevent compliance with the protocol or adherence to therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>31/07/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Actelion Phrmaceuticals Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Actelion Phrmaceuticals Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to investigate whether bosentan (Tracleer®) affects the wall thickness of the pulmonary arteries in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH related to systemic sclerosis (PAH-SSc)</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Camperdown</ethicaddress>
      <ethicapprovaldate>24/11/2005</ethicapprovaldate>
      <hrec>X05-0255</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tanya Robb</name>
      <address>Suite 6  13b Narabang Way
Belrose
NSW 2085</address>
      <phone>+61 2 9486 4600 Ext. 618</phone>
      <fax />
      <email>tanya.robb@actelion.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>David Celermajer, Professor</name>
      <address>Royal Prince Alfred Hospital
Missenden Road
New South Wales 2050</address>
      <phone>+61 2 9515 7110</phone>
      <fax />
      <email>david.celermajer@email.cs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>